Investigational Drug Details
| Drug ID: | D400 |
| Drug Name: | Eltrombopag |
| Synonyms: | Eltrombopag |
| Type: | Chemical drug |
| DrugBank ID: | DB06210 |
| DrugBank Description: | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. |
| PubChem ID: | -- |
| CasNo: | 496775-61-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC=CC(=C2)C(O)=O)=C1O)C1=CC=C(C)C(C)=C1 |
| Structure: |
|
| InChiKey: | XDXWLKQMMKQXPV-QYQHSDTDSA-N |
| Molecular Weight: | 442.467 |
| DrugBank Targets: | Thrombopoietin receptor agonist |
| DrugBank MoA: | Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Eltrombopag is a stimulator of STAT and JAK phosphorylation. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. It should be noted that when given to patients with aplastic anemia, other lineages besides platelet count were increased, suggesting that either eltrombopag enhanced the effect of TPO in vivo; or there is a yet uncovered mechanism of action at work. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 3 terminated (NCT00678587: GSK decision) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0364 | NCT00678587 | Phase 3 | Terminated | Has Results | June 2008 | October 12, 2018 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|